All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
Insilico teams up with Menarini for breast cancer KAT6 inhibitor
Menarini’s subsidiary Stemline will receive upfront and milestone payments, with a potential value exceeding $500m, along with royalties from sales.
Tango Therapeutics doses first patient with USP1 inhibitor trial
Tango received US Food and Drug Administration (FDA) clearance on its investigational new drug application for TNG348 in September 2023.
Boehringer reinforces interest in NASH with new $2bn deal
This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.
J&J seeks another FDA label for Rybrevant in NSCLC
This signifies the third submission in four months from J&J for the Rybrevant development programme.
2023 in review: Cancer vaccines dose up on advances with tailored approaches
As the number of patients with cancers continues to grow globally, research into personalised cancer vaccines is vital.
Sudo raises $116m to advance TYK2 programmes
Sudo plans to advance two tyrosine kinase 2 (TYK2) candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.
Bluebird seeks $250m raise as priority voucher gambit falls short
Bluebird bio will secure up to $250m after a surprise decision from the US Food and Drug Administration (FDA) to hold back a priority review voucher.
POINT’s prostate cancer trial meets primary endpoint as Lilly’s offer looms
The topline data announcement comes on the same day as Lilly further extends its tender offer for the acquisition of POINT.
Anagenex and Nimbus team up for small molecule drug discovery
The companies will prioritise challenging drug targets across multiple therapy areas, leveraging Anagenex’s AI platform.
Illumina to divest Grail after two years of lawsuits
Illumina aims to finalise the terms of this divestiture by the end of the second quarter of 2024.